Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Gallbladder Cancer; Biliary Tract Cancer; Liver Cancer; Precancerous Condition; Benign Hepatobiliary Disease; Healthy, no Evidence of Disease
Interventions: Other: Gene expression analysis; Other: Genomic analysis; Other: Protein expression analysis; Other: Proteomic profiling; Other: Polymerase chain reaction; Other: Mass spectrometry; Other: Immunohistochemistry; Other: Metabolomics profiling; Other: Methylation and epigenetic analysis; Other: Liquid biopsy analysis; Other: Laboratory biomarker analysis
Sponsors: Peking Union Medical College Hospital; OrigiMed., Inc.; GeneCast Biotechnology Co., Ltd.; YuceBio Technology Co., Ltd.
Not yet recruiting
Feeds
24313 items (24313 unread) in 74 feeds
Acinar Cell Carcinoma
(192 unread)
Acinic Cell Carcinoma
(77 unread)
Adenoid Cystic Carcinoma
(484 unread)
Adrenal Gland Cancer
(2256 unread)
Ampulla Of Vater
(172 unread)
Anal Cancer
(2221 unread)
Angiosarcoma
(402 unread)
Appendix Cancer
(391 unread)
Bile Duct Cancer
(3623 unread)
Brain and CNS
(3048 unread)
Carcinoid
(784 unread)
Endocrine/Neuroendocrine
(2488 unread)
Gall Bladder Cancer
(1080 unread)
Hemangioendothelioma
(446 unread)
Hepatoblastoma
(332 unread)
Pancreas
(412 unread)
Phyllodes
(214 unread)
PMP and Mucinous Tumors
(149 unread)
Rhabdomyosarcoma
(785 unread)
Sarcoma
(4757 unread)
Trials - Gall Bladder Cancer (21 unread)
-
Hepatobiliary Tumors Tissue Samples Acquisition
Posted: June 24th, 2020, 2:00pm GMT
-
Study of People With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Posted: June 12th, 2020, 2:00pm GMT
Conditions: Gastrointestinal Epithelial Cancer; Gastrointestinal Neoplasms; Cancer of Gastrointestinal Tract; Cancer, Gastrointestinal; Gastrointestinal Cancer; Colo-rectal Cancer; Pancreatic Cancer; Gall Bladder Cancer; Colon Cancer; Esophageal Cancer; Stomach Cancer
Interventions: Drug: Cyclophosphamide; Drug: Fludarabine; Biological: Tumor-Infiltrating Lymphocytes (TIL); Drug: Aldesleukin
Sponsors: Intima Bioscience, Inc.; Masonic Cancer Center, University of Minnesota
Recruiting -
Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers
Posted: June 12th, 2020, 2:00pm GMT
Conditions: Colorectal Carcinoma; Gastric Adenocarcinoma; Esophageal and GEJ Adenocarcinoma; Cholangiocarcinoma; Gallbladder Carcinoma
Interventions: Drug: tucatinib; Drug: trastuzumab; Drug: oxaliplatin; Drug: leucovorin; Drug: fluorouracil
Sponsor: Seattle Genetics, Inc.
Not yet recruiting -
Diagnostic Value of Endoscopic Ultrasound Elastography for Differential Diagnosis of Gallbladder Polyp
Posted: June 4th, 2020, 2:00pm GMT
Condition: Gallbladder Polyps or Masses Greater Than 8-10 mm in Size
Intervention:
Sponsor: Seoul National University Hospital
Not yet recruiting -
Comparing the Current Hydration Regimen for the ABC02 Chemotherapy Regimen Versus a Shorter Hydration
Posted: April 27th, 2020, 2:00pm GMT
Condition: Gallbladder Cancer
Interventions: Combination Product: Shortened hydration time and dispensary of Akynzeo; Combination Product: Standard of care
Sponsors: Imperial College Healthcare NHS Trust; Chugai Pharma UK Limited
Recruiting -
Two-in-one Covered and Uncovered Metal Stent
Posted: April 7th, 2020, 2:00pm GMT
Conditions: Extrahepatic Bile Duct Cancer; Pancreatic Cancer; Lymph Node Metastases; Gallbladder Cancer
Intervention: Device: Two-in-one stent
Sponsor: Ajou University School of Medicine
Recruiting -
Adjuvant Chemoradiation for Patients With High-risk reseCtable Extrahepatic chOlangiocaRcinoma and gallblaDder Cancer
Posted: April 3rd, 2020, 2:00pm GMT
Conditions: Biliary Tract Cancer; Extrahepatic Cholangiocarcinoma; Gallbladder Cancer
Interventions: Combination Product: Chemoradiation; Other: Observation
Sponsor: Sun Yat-sen University
Recruiting -
Validation of a Score That Predicts Residual Disease in Incidental Gallbladder Cancer
Posted: March 25th, 2020, 2:00pm GMT
Condition: Gallbladder Neoplasm Malignant Primary
Intervention: Procedure: Radical surgery
Sponsor: Emilio Ramos
Not yet recruiting -
Neoadjuvant Gemcitabine Plus Cisplatin With or Without Durvalumab in Resectable Biliary Tract Cancer
Posted: March 13th, 2020, 2:00pm GMT
Conditions: Biliary Tract Neoplasms; Gallbladder Cancer; Cholangiocarcinoma
Interventions: Drug: Durvalumab + Gem/Cis; Drug: Gem/Cis
Sponsors: Asan Medical Center; Samsung Medical Center
Recruiting -
The Incidence of Gallstones After Gastric Cancer Surgery
Posted: January 31st, 2020, 3:00pm GMT
Conditions: Gallstones; Gastric Cancer
Intervention: Procedure: Resection
Sponsor: Hepatopancreatobiliary Surgery Institute of Gansu Province
Recruiting -
Hepatic Arterial Infusion Chemotherapy With FOLFOX and Bevacizumab Plus Toripalimab Intravenously for Advanced Biliary Tract Cancer
Posted: January 6th, 2020, 3:00pm GMT
Condition: Advanced Biliary Tract Cancer
Intervention: Other: oxaliplatin, 5-fluorouracil and bevacizumab plus Toripalimab
Sponsor: Peking University
Not yet recruiting -
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers
Posted: December 26th, 2019, 3:00pm GMT
Condition: Advanced Biliary Tract Cancer
Intervention: Drug: Toripalimab plus Lenvatinib
Sponsors: Peking Union Medical College Hospital; Shanghai Junshi Biosciences Co., LTD
Not yet recruiting -
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
Posted: December 18th, 2019, 3:00pm GMT
Condition: Biliary Tract Cancer
Interventions: Drug: CPI 613; Drug: Gemcitabine; Drug: Cisplatin
Sponsor: University of Michigan Rogel Cancer Center
Recruiting -
Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma
Posted: August 16th, 2019, 2:00pm GMT
Condition: Cholangiocarcinoma
Intervention: Combination Product: Combination of Lonsurf® and Campto®
Sponsors: RWTH Aachen University; Servier
Not yet recruiting -
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Posted: June 27th, 2019, 2:00pm GMT
Conditions: Peripheral T Cell Lymphoma; Diffuse Large B Cell Lymphoma; Biliary Tract Cancer; Extranodal NK T Cell Lymphoma, Nasal
Intervention: Biological: STI-3031
Sponsor: Sorrento Therapeutics, Inc.
Not yet recruiting -
Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor
Posted: June 13th, 2019, 2:00pm GMT
Conditions: Tumor, Solid; Gall Bladder Cancer; Cervical Cancer; Colorectal Cancer; Gastric Cancer; Pancreatic Cancer; Clear Cell Renal Cell Carcinoma
Intervention: Drug: Andes-1537 for Injection
Sponsor: Andes Biotechnologies
Recruiting -
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
Posted: December 31st, 2018, 3:00pm GMT
Condition: Biliary Tract Cancer
Intervention: Drug: telotristat ethyl
Sponsor: Lexicon Pharmaceuticals
Recruiting -
Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
Posted: October 24th, 2018, 2:00pm GMT
Conditions: Pancreatic Cancer; Resectable Pancreatic Cancer
Interventions: Drug: Pimonidazole; Procedure: Surgical Resection
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Varian Medical Systems
Not yet recruiting -
Hepatic Resection for Metastatic Pancreatic Cancer
Posted: September 8th, 2016, 2:00pm GMT
Conditions: Pancreatic Neoplasms; Neoplasm Metastasis; Liver Metastases
Intervention: Procedure: Hepatic Resection or Ablation with Pancreaticoduodenectomy
Sponsor: Duke University
Recruiting -
Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery
Posted: August 11th, 2015, 2:00pm GMT
Conditions: Cholangiocarcinoma; Liver and Intrahepatic Bile Duct Carcinoma; Stage III Gallbladder Cancer AJCC v7; Stage III Intrahepatic Cholangiocarcinoma AJCC v7; Stage IIIA Gallbladder Cancer AJCC v7; Stage IIIB Gallbladder Cancer AJCC v7; Stage IV Gallbladder Cancer AJCC v7; Stage IVA Gallbladder Cancer AJCC v7; Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7; Stage IVB Gallbladder Cancer AJCC v7; Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7; Unresectable Gallbladder Carcinoma
Interventions: Other: Laboratory Biomarker Analysis; Biological: Ramucirumab
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Recruiting -
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
Posted: March 11th, 2011, 3:00pm GMT
Conditions: Non-GI Cancers; Cancer of Gastrointestinal Tract; Gastrointestinal Cancer
Intervention:
Sponsor: National Cancer Institute (NCI)
Recruiting